Navigation Links
A Successful Launch of a New Oncology Product Requires Global Teams & Planning

CHAPEL HILL, N.C., Nov. 1, 2012 /PRNewswire/ -- Global Strategic Marketing (GSM) organizations in oncology and other critical therapeutic areas often face crowded markets that require high performance and proficiency to be successful.

Add to this increasing regulatory challenges, regional differences and the competitive nature of the oncology marketplace and it is easy to understand why GSM organizations to constantly assess their budgets and resource planning strategies to ensure a successful product launch.

To help marketing leaders throughout the pharma and medical device industries better equip their global strategy groups, Best Practices, LLC conducted and delivered "Oncology Global Strategic Marketing: Benchmarking Budget Levels & Service Scope," a primary research study which identifies essential insights for Oncology-GSM leaders in budgeting and strategic planning. 

This report seeks to help companies understand the investment levels, marketing activities, timing and structures needed to successfully steer products and pipeline programs through the complex Oncology marketplace.

Executives can use this 75-page report to compare their global strategic marketing budget, staffing and services levels with industry averages to enhance their current practices.

Sample study benchmarks available in this report include:

  • GSM staffing benchmarks by role, by development phase, by number of oncology programs and per $100M in oncology sales
  • Outsourced and in-house labor dedicated to traditional and emerging markets
  • GSM organizational structure
  • Role of the GSM function for activities such as market intelligence, marketing, advocacy and KOL management
  • Spending benchmarks around key GSM activities within marketing, market intelligence and advocacy
  • Oncology GSM spending by phase of clinical development

Research participants included Global Strategic Marketing leaders supporting oncology organizations at 17 companies, including 11 of the Top 25 pharma companies. The study included both large, established and small, emerging oncology companies to provide broadest insights.

A complimentary excerpt of the research report is available at:

For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at

BEST PRACTICES, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies.

The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.

SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
6. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
8. Pharmos Corporation Announces Successful Completion Of Proof-of-concept Clinical Trial Of Levotofisopam For The Treatment Of Gout
9. Acuo Technologies Grows European Business and Achieves Successful Connectathon Results in Bern, Switzerland
10. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
11. Concord Medical Announces its Successful Closing of the Acquisition of 52% Ownership in Changan Hospital and Provides Guidance for Financial Results of the Second Quarter of 2012
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):